查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1917783

缓释药物递送市场－2026-2031年预测

Controlled Release Drug Delivery Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计缓释药物输送市场将从 2025 年的 539.02 亿美元成长到 2031 年的 941.38 亿美元，复合年增长率为 9.74%。

缓释药物递送系统透过确保药物浓度稳定，进而维持治疗效果并提高慢性病管理的用药依从性，推动市场发展。不断增加的研发投入正在推动新技术的发展，这些新技术能够实现精准且持续的药物释放。学名药生产的扩大为患者提供了更具成本效益的缓释药物选择。人口老化也促使人们寻求更安全、用药频率更低的长期治疗方案。

缓释药物递送系统可在较长时间内维持最佳活性成分浓度，从而提高疗效并最大限度地减少浓度波动。这些平台可减少给药频率，提高病患依从性和便利性，同时也能减少因峰谷波动引起的副作用。在慢性病负担日益加重、监管支持、技术进步以及老年人老化导致持续治疗需求增加等因素的推动下，该市场正稳步扩张。

关键成长要素包括缓释製剂的固有优势，例如维持治疗浓度、减少给药频率和提高疗效，这些优势对于需要持续治疗的疾病尤其重要。慢性病盛行率的不断上升，使得可靠的长效製剂成为优化治疗方案和减少併发症的必要手段。学名药的普及使得品牌药等效的缓释製剂能够以可负担的价格广泛供应，并符合确保生物等效性和品质的监管途径。机构研发投入的增加正在加速递送机制的创新，包括多颗粒、基质和渗透系统。人口快速老化，生理机能下降，以及用药依从性方面的挑战，导致多种药物联合使用，并促使人们寻求减少给药频率、提高耐受性的给药方案，以维持生活品质。

从区域来看，由于慢性病发病率上升、医疗费用支出高企、监管政策支持、人口老龄化以及强大的创新生态系统，北美预计将实现显着增长并保持稳定的市场份额。该地区蓬勃发展的非专利产业也进一步推动了缓释製剂的应用。

主要企业包括 Adare Pharma Solutions，这是一家全球 CDMO，专门从事使用多颗粒、基质系统、渗透平台和包衣颗粒的缓释口服剂型，提供个性化的缓释特性；Colorcon 在薄膜包衣技术方面表现出色，例如 Opadry®，可提高固态剂型的耐久性、外观和控释控制释放； Pembrolizumab）、Januvia®（sitagliptin）、 Gardasil（人类乳突病毒(HPV)疫苗）和 ProQuad®（麻疹-水痘合併疫苗）等产品。

总体而言，在慢性病日益增多和人口结构变化的背景下，人们期望解决依从性、治疗方法优化和可及性方面的障碍，这推动了市场强劲成长。聚合物、涂层和渗透技术的不断进步正在扩大其临床效用范围。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略进入市场的机会。
  • 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
  • 可操作的建议：利用这些见解，在动态环境中做出策略决策，并开拓新的商机和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

企业如何使用我们的报告？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

研究范围：

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

5. 按技术分類的缓释药物递送市场

  • 介绍
  • 微胶囊化
  • 经皮吸收
  • 定向投放
  • 其他的

第六章 缓释药物递送市场：依释放机制划分

  • 介绍
  • 聚合物基体系
  • 微储库控制药物输送系统
  • 回馈控制药物传输系统
  • 启动控制药物递送系统
  • 化学活化

第七章 缓释药物递送市场：依应用领域划分

  • 介绍
  • 定量喷雾吸入器
  • 注射
  • 经皮和眼用贴剂
  • 其他的

8. 按地区分類的控释药物递送市场

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十章：公司简介

  • Adare Pharma Solutions
  • Merck and Co., Inc
  • Colorcon
  • Coating Place
  • GlaxoSmithKline PLC
  • Lonza
  • Bayer Healthcare LLC
  • Orbis Biosciences Inc.
  • Alkermes PLC
  • Pfizer Inc.

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061615754

Controlled Release Drug Delivery Market is forecasted to rise at a 9.74% CAGR, reaching USD 94.138 billion in 2031 from USD 53.902 billion in 2025.

The controlled release drug delivery market is advancing as systems ensure steady therapeutic levels, enhancing compliance in chronic disease management. Rising R&D investments are fueling novel technologies for precise, prolonged release profiles. Growth in generic production is delivering cost-effective controlled-release options. Aging populations are amplifying demand for safer, less frequent dosing regimens in long-term therapies.

Controlled release drug delivery systems maintain optimal API concentrations over extended periods, minimizing fluctuations and improving efficacy. These platforms reduce dosing frequency, boosting patient adherence and convenience while mitigating side effects from peak-trough variations. The market is expanding steadily, supported by chronic disease burden, regulatory encouragement, technological progress, and demographic shifts toward elderly cohorts requiring sustained treatments.

Key growth drivers include the inherent benefits of controlled release, such as sustained therapeutic levels, fewer administrations, and enhanced outcomes, particularly valuable for conditions demanding consistent management. Escalating chronic disease prevalence necessitates reliable, long-acting formulations to optimize control and reduce complications. Expansion of the generic segment enables broader access to affordable controlled-release equivalents of branded drugs, aligned with regulatory pathways ensuring bioequivalence and quality. Heightened R&D expenditure, backed by institutional funding, accelerates innovations in delivery mechanisms like multiparticulates, matrix, and osmotic systems. The burgeoning aging population, with diminished physiological resilience and adherence challenges, favors low-frequency, tolerable dosing to support polypharmacy and quality of life.

Geographically, North America is projected for significant growth and share retention, attributed to elevated chronic disease rates, substantial healthcare spending, supportive regulations, geriatric demographics, and robust innovation ecosystem. The region's thriving generic industry further catalyzes controlled-release adoption.

Leading companies include Adare Pharma Solutions, a global CDMO specializing in oral dosage forms with controlled release via multiparticulates, matrix systems, osmotic platforms, and coated pellets for tailored, extended profiles. Colorcon excels in film coatings like Opadry(R) to enhance durability, aesthetics, and release control in solid dosages. Merck & Co., Inc. develops and markets pharmaceuticals incorporating advanced delivery, exemplified by products like Keytruda(R) (pembrolizumab), Januvia(R) (sitagliptin), Gardasil(R) (HPV vaccine), and ProQuad(R) (measles/varicella vaccine).

Overall, the market is progressing robustly, positioned to address adherence barriers, therapeutic optimization, and accessibility amid chronic disease escalation and demographic transitions, with ongoing advancements in polymer, coating, and osmotic technologies broadening clinical utility.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Controlled Release Drug Delivery Market Segmentation

  • By Technology
  • Micro Encapsulation
  • Transdermal
  • Targeted Delivery
  • Others
  • By Release Mechanism
  • Polymer Based Systems
  • Micro Reservoir Partition Controlled Drug Delivery Systems
  • Feedback Regulated Drug Delivery Systems
  • Activation-modulated Drug Delivery Systems
  • Chemically Activated
  • By Application
  • Metered Dose Inhalers
  • Injectable
  • Transdermal and Ocular Patches
  • Others
  • By Geography
  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CONTROLLED RELEASE DRUG DELIVERY MARKET BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Micro Encapsulation
  • 5.3. Transdermal
  • 5.4. Targeted delivery
  • 5.5. Others

6. CONTROLLED RELEASE DRUG DELIVERY MARKET BY RELEASE MECHANISM

  • 6.1. Introduction
  • 6.2. Polymer Based Systems
  • 6.3. Micro Reservoir Partition Controlled Drug Delivery Systems
  • 6.4. Feedback Regulated Drug Delivery Systems
  • 6.5. Activation-modulated Drug Delivery Systems
  • 6.6. Chemically Activated

7. CONTROLLED RELEASE DRUG DELIVERY MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Metered Dose Inhalers
  • 7.3. Injectable
  • 7.4. Transdermal and Ocular Patches
  • 7.5. Others

8. CONTROLLED RELEASE DRUG DELIVERY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Adare Pharma Solutions
  • 10.2. Merck and Co., Inc
  • 10.3. Colorcon
  • 10.4. Coating Place
  • 10.5. GlaxoSmithKline PLC
  • 10.6. Lonza
  • 10.7. Bayer Healthcare LLC
  • 10.8. Orbis Biosciences Inc.
  • 10.9. Alkermes PLC
  • 10.10. Pfizer Inc.

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations